X4 Pharmaceuticals Elects New Director at Annual Meeting

The latest announcement is out from X4 Pharmaceuticals ( (XFOR) ).

On June 9, 2025, X4 Pharmaceuticals held its annual stockholders meeting where key proposals were voted on. Stockholders elected R. Keith Woods as a director, ratified PricewaterhouseCoopers LLP as the independent accounting firm for 2025, and approved executive compensation in a non-binding vote. These decisions are pivotal for the company’s governance and financial oversight, potentially impacting its strategic direction and stakeholder confidence.

The most recent analyst rating on (XFOR) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on X4 Pharmaceuticals stock, see the XFOR Stock Forecast page.

Spark’s Take on XFOR Stock

According to Spark, TipRanks’ AI Analyst, XFOR is a Neutral.

X4 Pharmaceuticals faces significant financial challenges, notably in profitability and cash flow, despite growth in revenue. Technical indicators suggest a downward trend, while valuation metrics indicate potential undervaluation. The earnings call and recent corporate events offer some optimism with strategic initiatives and clinical progress, but market and sales challenges remain.

To see Spark’s full report on XFOR stock, click here.

More about X4 Pharmaceuticals

X4 Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on developing innovative therapies for patients with rare diseases. The company is committed to advancing its pipeline of products to address unmet medical needs.

Average Trading Volume: 163,534

Technical Sentiment Signal: Sell

Current Market Cap: $20.61M

For a thorough assessment of XFOR stock, go to TipRanks’ Stock Analysis page.